Agomab Therapeutics NV

Agomab Therapeutics NVAgomab Therapeutics NV
Agomab Therapeutics NV

Agomab Therapeutics NV

Biotech company developing novel therapeutics for fibrotic diseases.

Website
DR 302017Active74Ghent, Belgium
Rate
Advertise here

About

Agomab Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for fibrotic diseases. Their lead drug candidate, AGMB-101, targets the underlying mechanisms of fibrosis, aiming to halt or reverse disease progression in conditions like idiopathic pulmonary fibrosis (IPF) and liver fibrosis.
Frequently asked

What does Agomab Therapeutics NV do?

Agomab Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for fibrotic diseases. Their lead drug candidate, AGMB-101, targets the underlying mechanisms of fibrosis, aiming to halt or reverse disease progression in conditions like idiopathic pulmonary fibrosis (IPF) and liver fibrosis.

What is Agomab Therapeutics NV's revenue?

StartupHub estimates Agomab Therapeutics NV's annual revenue at $16.2M (range $8.8M to $37.3M, 65% confidence), based on comparable companies in the sector.

Where is Agomab Therapeutics NV headquartered?

Agomab Therapeutics NV is headquartered in Ghent, Belgium.

When was Agomab Therapeutics NV founded?

Agomab Therapeutics NV was founded in 2017.

What industry does Agomab Therapeutics NV operate in?

Agomab Therapeutics NV operates in Biotech, MedTech, Drug Discovery, Clinical Trials, Fibrosis, Therapeutics.

How many employees does Agomab Therapeutics NV have?

Agomab Therapeutics NV has approximately 74 people on record.

HEADCOUNT
74
DOMAIN RATING
30
Comments

No comments yet. Be the first to share your take.